Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (221-230 of 344) with videos related to

Pageof 35
Sort By:
Clinical Colorectal Cancer|February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal CancerTakayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2011
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancerKohei Shitara, Takashi Ura, Keitaro Matsuo, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
JCO Precision Oncology|March 21, 2025
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 StudiesYelena Y Janjigian, Michael Cecchini, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 16, 2015
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patientsNozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata, et al.
The New England Journal of Medicine|May 30, 2020
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric CancerKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Cancer Research Communications|December 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric CancerShigehiro Koganemaru, Shohei Koyama, Fumitaka Suto, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2025
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplificationsTaroh Satoh, Philippe Barthélémy, Lucia Nogova, et al.
Cancer Science|March 2, 2024
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potentialTadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, et al.
Pageof 35

Showing results (221-230 of 344) with videos related to

Sort By:
Pageof 35
Clinical Colorectal Cancer|February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal CancerTakayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2011
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancerKohei Shitara, Takashi Ura, Keitaro Matsuo, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
JCO Precision Oncology|March 21, 2025
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 StudiesYelena Y Janjigian, Michael Cecchini, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 16, 2015
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patientsNozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata, et al.
The New England Journal of Medicine|May 30, 2020
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric CancerKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Cancer Research Communications|December 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric CancerShigehiro Koganemaru, Shohei Koyama, Fumitaka Suto, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2025
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplificationsTaroh Satoh, Philippe Barthélémy, Lucia Nogova, et al.
Cancer Science|March 2, 2024
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potentialTadayoshi Hashimoto, Yoshiaki Nakamura, Saori Mishima, et al.
Pageof 35